Article · 30 Apr 2025
Case reportPublished 28 Feb 2023
A case report of hemophagocytic lymphohistiocytosis (HLH) brought on by EBV reactivation on durvalumab.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The condition known as hemophagocytic lymphohistiocytosis poses a major threat to life. So, in order to decrease mortality, it is crucial to understand how to identify it and treat it swiftly. Methods: In this paper, a case of a 60-year-old female patient with recurrent ovarian cancer is presented. Durvalumab, Bevacizumab, Olaparib, and Durvalumab were all used in her treatment. Her syndrome, which was promptly identified as Hemophagocytic Lymphohistiocytosis (HLH), included fever, dyspnea, anaemia, and thrombocytopenia. The patient's clinical condition was able to normalise thanks to the quick start of the Etoposide, Dexamethasone, and Type G Immunoglobulin treatments. Results: We propose two potential origins for this syndrome: first, an infectious origin caused by EBV, as well as an immunological origin caused by durvalumab. The patient's clinical condition was able to normalise thanks to the quick start of the Etoposide, Dexamethasone, and Type G Immunoglobulin treatments. To implement a curative treatment as soon as feasible with a reduction in its mortality as our goal, it is crucial to raise awareness about HLH and its causes.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Audrey Maury”